Oliver, and revenue to compared quarter year you, I financial second was to quarter second and the XXXX. welcome of Thank OpGen’s results. XXXX in approximately the everyone quarter $XXX,XXX of $XXX,XXX, half for on call. revenue the highlights and will discuss first second
compared of of XXXX of half revenue half first First of in $X.XX million the $X.XX million approximately XX%, by approximately approximately grew to revenue XXXX.
Acuitas as Ares received service Gene XXXX was the collaboration as revenue due our AMR revenues. included in commercial generated sales, revenue the under FIND contracts, also project, increase to product related from This primarily but Panel Unyvero we well
of the and Unyvero second on work and we U.S. existing Acuitas, For customer in as recently as from generating particular. XXXX, well agreements, for collaborations half commercial several to including U.S. customers plan contracts from the in the new signed commercial revenue in
Our XXXX. total quarter $X.X second comparable in operating million to $X.X in quarter of for XXXX the compared million, the expenses decreased to
the months For in period half saw comparable of $XX.X of XXXX, million we million operating first XXXX a in the $XX.X decrease six from to year. the expenses this X% first approximately in of
a or payroll-related as costs, the development quarter was expense XXXX quarter conclusion well corresponding of to the reduction Unyvero and million compared of mainly i.e., of third was trial due second reduction. This as multicenter for in in clinical period Our research $X.X decrease XXXX. year, prospective a million, $X.X XX% to previous UTI the for the R&D the
was in $X.X $X.X expense compared of million, R&D during first half million half to the XXXX. First XXXX
of compared of Our $X.X for year-over-year XXXX $X.X period second quarter XXXX $X.X the XXXX of expense G&A million. and first corresponding million, to half previous G&A general million first consistent expense was administrative and remained year. the at the or half the with
first the marketing second and XXXX. sales the million first of of stayed quarter $X.X approximately the $X.X for XXXX Our both of sales the expenses million Similarly, at marketing XXXX. second consistent stayed half half of quarter consistent and expenses and approximately for and XXXX at both
as look position million. had XX, of a cash, position. with of at XXXX, June our cash cash a We XXXX approximately $X.X ended approximately Taking we and $X.X million
direct in Unyvero in marketing and year, public products; the to test and Ares services; our we the the collaborators of AMR subsidiaries. to offerings and for customers the of of and Panel of for database offering. invest following; repay Acuitas Gene the our support and May development commercialize products intend and platforms support tests; a the In early Genetics proceeds platform on of support the announced invest infrastructure sales these the related all offerings; We a continued outstanding sale our and service this and certain FDA-cleared the further with indebtedness company of the and our products diagnostic use manufacturing continue Unyvero its closing focus commercialization $X.X R&D in products; to from million for of and to efforts operations commercialization and U.S.; support
met two deferred year, pool April tranche million plus Having principle €X respectively, of from obligations by of our be repaid. debt are million, interest in this first to and accumulated tranches our the €X repayment there additional and EIB debt
a While in that million the of until second upcoming agreement with on in XX, partial signed both EIB parties tranche such such stay the €X standstill further payment of a agree best outstanding debt and time initially restructuring the earlier following we provide their June, became or on of due us in June repayments. interest repayment XXXX by the or November XXXX, tranche
and and that cash position, current sufficient operations our debt not temporary the to of repayment Notwithstanding do of September our be performance as in our reported light stay XXXX. business we beyond expect previously will current fund on cash
the have doubt OpGen’s we Since pursued is second our to shortfall. the ability quarter, substantial of options a position continue concern. mitigate there to cash a or about Nevertheless, liquidity going as end improve
including alternatives, consider laws. other equity under our as reducing for our including additional refinancing as relief or or activities, restructuring measures, well all capital, strategic We seeking and continue other obtaining selling U.S., transactions or business bankruptcy to debt, delaying debt assets, applicable
of successfully successful. these is these unable will on to If and identify of alternatives operating insufficient that be of be cash able execute guarantee that alternatives, the no execute are any company on have There XXXX. to any and September or beyond we to continue any will identify them will we
receipt second is the to to to opportunities a end The cash continued situation our as order quarter, in such we our highlights continue of revenue concern. on our and several had going the revenue from being generation. since able relating commercial of mitigate premised During have
we half After, have recognized scope FIND Curetis from the at on in XXXX. extending this more revenue $XXX,XXX collaboration contract. of FIND $XXX,XXX of XXXX, from the project the and revenue in we first in in than agreed approximately The had teams recognized the
at development, culture for income will in assay phase middle of vitro diagnostic an looking The test software as AMR or full and resistance low in as next well LMICs. testing or antimicrobial and blood samples analytical countries development be
and is about up months XX phase to activities. approximately budget This next take for assigned $XXX,XXX expected of an aforementioned has the to
became development payment certain upon the form The of three about of and equally due be packages not amount coming [ph] shown $XXX,XXX the in the coming the would first data tranches remaining signing of extension of delivery in quarters. contract upon sized two and
development the LMICs regulatory is and in launch us. FIND seeking future such trials, and to and for between subject the be would possible countries Subsequent expansions contract commercial submissions of market these preparing needed approval collaboration phases, clinical as specific for further
for parties such of conditions will Third license would license AXX become faith agreed that good platform a certain the terms the in LMICs in to is and have the they negotiate also that necessary. and future
products second Unyvero we including, to our we revenue into to for with Fisher Furthermore, in Ares with Unyvero globally particular, continue see Genetics for here in our quarter. entered services partnership during that especially the distribution Healthcare U.S., and the opportunities growth and products respect our
We and partnership. expect building to see our the traction sales Unyvero U.S. in under this distribution for momentum
a children’s from Unyvero several further U.S., with and with a pneumonia Acuitas of hospital We blood as diagnostics hospitals contract in Lab a larger customer. for prestigious account, culture contracts another have for global Unyvero BAL hospital system multiyear LRT customer Western across for customers network an also as signed placements U.S. a the well a here UTI as testing, Unyvero new Unyvero account recently with a adding strategic the corporate including reference
placements for contracts potential with During demonstrating the signed product second also two one lines. system of our customers, new scientific our quarter, of Unyvero Acuitas we
are is offerings Our cloud-based in ROU Acuitas adding dialogue portfolio team see accounts of AMR. for these across of to some of with some and our IVD our Ares we offerings upselling also starting opportunities active accounts. ISS and Ares opportunities cross-selling Ares Thus, in and about entire
annualized Taken have to adding revenue revenue contracts our weeks, to we topline commercial of up together, growth signed potential. $X.X million, potential in totaling recent volume
to-date, Beyond a a OpGen. contracted total non-dilutive in additional priority million of $X.X financing to strategic FIND for up remain funding opportunities
with partner BARDA, look equity bodies. funding we collaboration to other expand like funding year-to-date, complement the with will could our opportunities allow and us shown potential organizations that and to FIND, Union European these As
funding key vital ranged for of XXX% able full none ensure likely funding co-funding to materialize. these It projects. is is the funding somewhere non-dilutive XX% opportunities It is quotas understand to these in non-dilutive XX% XX% own ranges. of that therefore the for to not funding respective to that its from provide Typically, or provide OpGen maybe Otherwise, projects. would
I financial will This concludes call the now back turn to the update. Oliver.
